Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism

Rui Chen, Lea K. Davis, Stephen Guter, Qiang Wei, Suma Jacob, Melissa H. Potter, Nancy J. Cox, Edwin H. Cook, James S. Sutcliffe, Bingshan Li

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Background: Autism spectrum disorder (ASD) is one of the most highly heritable neuropsychiatric disorders, but underlying molecular mechanisms are still unresolved due to extreme locus heterogeneity. Leveraging meaningful endophenotypes or biomarkers may be an effective strategy to reduce heterogeneity to identify novel ASD genes. Numerous lines of evidence suggest a link between hyperserotonemia, i.e., elevated serotonin (5-hydroxytryptamine or 5-HT) in whole blood, and ASD. However, the genetic determinants of blood 5-HT level and their relationship to ASD are largely unknown. Methods: In this study, pursuing the hypothesis that de novo variants (DNVs) and rare risk alleles acting in a recessive mode may play an important role in predisposition of hyperserotonemia in people with ASD, we carried out whole exome sequencing (WES) in 116 ASD parent-proband trios with most (107) probands having 5-HT measurements. Results: Combined with published ASD DNVs, we identified USP15 as having recurrent de novo loss of function mutations and discovered evidence supporting two other known genes with recurrent DNVs (FOXP1 and KDM5B). Genes harboring functional DNVs significantly overlap with functional/disease gene sets known to be involved in ASD etiology, including FMRP targets and synaptic formation and transcriptional regulation genes. We grouped the probands into High-5HT and Normal-5HT groups based on normalized serotonin levels, and used network-based gene set enrichment analysis (NGSEA) to identify novel hyperserotonemia-related ASD genes based on LoF and missense DNVs. We found enrichment in the High-5HT group for a gene network module (DAWN-1) previously implicated in ASD, and this points to the TGF-β pathway and cell junction processes. Through analysis of rare recessively acting variants (RAVs), we also found that rare compound heterozygotes (CHs) in the High-5HT group were enriched for loci in an ASD-associated gene set. Finally, we carried out rare variant group-wise transmission disequilibrium tests (gTDT) and observed significant association of rare variants in genes encoding a subset of the serotonin pathway with ASD. Conclusions: Our study identified USP15 as a novel gene implicated in ASD based on recurrent DNVs. It also demonstrates the potential value of 5-HT as an effective endophenotype for gene discovery in ASD, and the effectiveness of this strategy needs to be further explored in studies of larger sample sizes.

Original languageEnglish (US)
Article number14
JournalMolecular Autism
Volume8
Issue number1
DOIs
StatePublished - Mar 21 2017

Bibliographical note

Funding Information:
The UIC Autism Center of Excellence was supported by P50HD055751 (LD, SJ, NC, EC, JS) from NICHD/NINDS/NIEHS. Sequencing services were provided by the Center for Inherited Disease Research (CIDR) through X01 HG007235. CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268201200008I. The study was also supported by R01 MH089482 (JS), P50MH094267 (EC, NC) and a Lever Award from the Chicago Biomedical Consortium. The analysis of the data was supported by R01HG006857 (RC, QW, and BL).

Publisher Copyright:
© 2017 The Author(s).

Keywords

  • 5-HT
  • Autism
  • Autism spectrum disorder
  • Compound heterozygotes
  • De novo mutation
  • Endophenotype
  • Group-wise transmission/disequilibrium test
  • Hyperserotonemia
  • Rare variants
  • Serotonin
  • Whole exome sequencing

Fingerprint

Dive into the research topics of 'Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism'. Together they form a unique fingerprint.

Cite this